Autonomix Medical, Inc.: Business Overview, Financials & Competitive Analysis
Autonomix Medical, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). First-in-class transvascular neural sensing-ablation platform with durable clinical signals but binary regulatory and commercialization risk. Autonomix demonstrates differentiated technology with strong IP protection and early clinical validation (preliminary positive results from first-in-human study); however, as a pre-revenue development-stage company with micro-cap status ($300M market cap range) and upcoming FDA.
What is Autonomix Medical, Inc.'s industry? Autonomix Medical, Inc. (autonomixmedical.com) operates in Neurostimulation Devices. AskCyborg classifies Autonomix Medical, Inc. under Neurostimulation Devices in its company registry.
Autonomix Medical is a development-stage medical device company focused on advancing catheter-based microchip technologies for sensing and treating disorders of the peripheral nervous system. The company's first-in-cl...
Cyborg Score thesis
First-in-class transvascular neural sensing-ablation platform with durable clinical signals but binary regulatory and...
Read the full analyst-debate transcript →Get the Latest Autonomix Medical, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAutonomix Medical, Inc. Overview
Pro stress-test →Autonomix Medical is a development-stage medical device company focused on advancing catheter-based microchip technologies for sensing and treating disorders of the peripheral nervous system. The company's first-in-class platform enables precision nerve-targeted therapies with approximately 3,000 times greater neural signal sensitivity than existing technologies, initially targeting pancreatic cancer pain but with potential across cardiology, hypertension, and chronic pain indications.
Strategic Profile
Pro stress-test →Autonomix positions itself as a category-defining innovator in transvascular neuromodulation, leveraging a proprietary sensory-ablation platform (sense-treat-verify workflow) protected by 18 patent families and 120+ applications. The company is advancing from animal studies and first-in-human clinical data toward FDA submission, representing a high-risk, high-reward play in an emerging market segment with minimal direct competition in transvascular peripheral nerve intervention.
Competitive Landscape
Pro stress-test →Autonomix operates in an emerging transvascular neuromodulation segment with minimal direct competition; however, it faces indirect competition from established neuromodulation players (Abbott, Medtronic) and interventional oncology platforms. The company's differentiated microchip-sensing approach and first-mover advantage in transvascular access for peripheral nerve targeting provide competitive separation, though larger device makers have manufacturing scale and regulatory relationships.
Industry Context
Autonomix Medical, Inc. operates in Neurostimulation Devices.
Key facts
Founded: 2014 · Headquarters: The Woodlands, Texas, US · Employees: Not disclosed · Revenue: Pre-revenue (development stage) · Market cap: ~$300M